UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39503 Athira Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 45-3368487 (State or other jurisdiction of ...

Athira Pharma, Inc. (NASDAQ:ATHA) Q4 2021 Earnings Conference Call March 24, 2022 4:30 PM ET Company Participants Julie Rathbun - Investor Relations Mark Litton - President & Chief Executive Officer Hans Moebius - Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies Paul Matteis - Stifel Corinne Jenkins - Goldman Sachs Jason Butler - JMP Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are ...